PRIUM Educational Services Managing Drugs & Chronic Pain in Work Comp
|
|
- Mildred Black
- 5 years ago
- Views:
Transcription
1 PRIUM Educational Services Managing Drugs & Chronic Pain in Work Comp
2 Your Speaker Mark Pew, Senior Vice President of Product Development PRIUM ( Medical Intervention on Clinically Complex Claims Mr. Pew brings over 30 years of expertise in the property and casualty and healthcare industries, strategic planning, and technology to his presentations. He has worked with PRIUM in a variety of roles since 1989 including IT, operations, product and service development, and executive management. Other experience includes CoreSpeed, MedicaView International, ChoicePoint and Equifax. Mr. Pew has been following the prescription drug issue since 2003 and created PRIUM s Medical Intervention Program. Current responsibilities at PRIUM include marketing, product development and educational outreach.
3 Learning Objectives 1. Review the prescription drug issue in the US and Work Comp 2. Define opioids and clarify when to and how to use them 3. Define other prescription drugs and Polypharmacy 4. Recognize inappropriate treatment patterns and red flags 5. Outline the weaning process 6. Identify methods to identify and implement treatment plan changes Additional Resources: Katrina Disaster Working Group, 2006 FDA Blueprint, 2011 Responding to America s Prescription Drug Abuse Crisis, 2011 Pacing functional restoration, 2013
4 The Drug Problem U.S. Culture The CDC calls it an epidemic and health crisis The US comprises 4.5% of world population yet consumes: 65% of all illegal drugs 80% of all opioids 49% of all morphine 99% of all hydrocodone Sources: Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007; 297: Manachikanti, Laxmaiah, and Singh, Angelie, Therapeutic Opioids: A Ten-Year Perspective of the Complexities and Complications of Escalating Use, Abuse, and Nonmedical Use of Opioids. Pain Physician, March 2008 Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Non-prescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee Meeting, June 20-30, 2009 Per the AMA Guides March/April 2011 Newsletter, non-compliance (misuse, overuse, non-consumption) occurred in more than 70% of patients According to the National Survey on Drug Use and Health ( ) 70% of America s first-time prescription drug abusers got the drugs from family and friends
5 The Drug Problem Workers Compensation According to NCCI s Workers Compensation Prescription Drug Study: 2013 Update Prescription drugs are, on average, 18% of medical costs CompPharma estimates 12-14% in 2013 Narcotics account for 25% of drug costs Physician dispensing was 17% of total paid Rx in 2011 Costs are driven more by utilization than price According to CompPharma s 2013 Prescription Drug Survey Employers and insurers will spend $4B on prescription drugs in 2013 According to the National Drug Intelligence Center OxyContin / Opana street price is between $.50 - $1 per milligram
6 The Drug Problem Physicians It is easier to write a prescription than to come to an understanding with the patient. -- Franz Kafka Physician dispensed drugs creates improper motivations ( easy and profitable program ) It s about revenue Per CWCI research paper (February 2013) As of 2011, over half of all prescriptions were physician dispensed Patient had up to 5 pharmacies within 2.2 miles of physician s office
7 The Drug Problem Opioids 2011 study on opioid discontinuance trends Almost 30,000 patients (primarily private health plans) prescribed opioids continuously for at least 90 days during a 6-month period Approximately 66% were still on opioids after 5 years Attributing factors were: Intermittent prior opioid exposure Daily opioid dose > 120mg MED Possible opioid misuse Source: Martin BC, et al. Long-term chronic opioid therapy discontinuation rates from the TROUP study. J Gen Intern Med Dec; 26(12): , study of non-specific, low back-pain Work Comp cases Costs escalate as work loss persists Odds 6x greater for chronic (> 90 days) work loss with Schedule II opioids Odds 11-14x greater with opioids of any kind during period of 90 days Post-injury 3 years, costs of claims with Schedule II opioids averaged $19,453 higher Source: Volinn E, et al. Opioid therapy for nonspecific low back pain and the outcome of chronic work loss. PAIN Volume 142, Issue 3 (April 2009), pages , Abstract
8 Opioids Defined Opioid (narcotic) Pain Purpose: Relieve pain by acting directly on the central nervous system (oral, topical). Refills are generally prohibited without new script Possible Side Effects: Sedation, drowsiness, impairments, constipation, respiratory depression, nausea, headache, stomach pain. Extremely high potential for abuse, dependence, addiction and diversion On-label Uses: Before/during/immediately after surgery, cancer and AIDS patients Reasonable Off-label Uses: Lowest effective dose to decrease pain, increase function, improve quality of life Red Flags: Used more than 6 contiguous months, aggregate dosage exceeds 120mg MED/day, DOI of more than 3 years, no change in levels of pain or function Examples: Actiq (Fentanyl lollipop), Exalgo (Hydromorphone ER), Avinza / Kadian (Morphine ER), OxyContin (Oxycodone ER), Nucynta (Tapentadol), Duragesic (Fentanyl transdermal), Ultram (Tramadol)
9 Opioids Defined Risk management before prescribing Prior substance abuse Personal or family substance abuse history Test: Diagnostic Criteria for Substance Dependence DSM-IV from the American Psychiatric Association Potential addiction/dependence issues Adverse childhood experiences (ACE), Neglect Physical, emotional, sexual abuse Test: Opioid Risk Tool (ORT), Screener and Opioid Assessment for Patients with Pain (SOAPP) Psychological makeup Mental illness Psychological stress (chemical coping) Test: Patient Health Questionnaire (PHQ-9)
10 Opioids Defined What Official Disability Guidelines (ODG) say about Opioids Establish a treatment plan Are there reasonable alternatives, is the patient likely to improve, screened for the risk of addiction, therapeutic trial only after non-opioid therapy has failed Determine if pain is nociceptive or neuropathic and any underlying psychological issues, set goals, pain agreement, discussion of risks Initiating therapy For intermittent pain, start with short-acting opioid, one drug at a time For continuous pain, use extended-release opioids Only change one drug at a time Establish opioid treatment agreement If partial analgesia is not obtained, discontinue opioids Ongoing management Only one prescriber and one pharmacy Lowest possible dose to improve pain and function Drug screening Regular pain assessment to gauge improvement (or lack thereof) in pain control and function
11 Opioids Defined What ODG says about Opioids When to discontinue opioids No overall improvement or decrease in function Continuing pain with lack of significant benefit from opioids If serious non-adherence (to dosage, to opioid treatment agreement, illegal activity) is occurring The patient requests discontinuance Resolution of pain When to continue opioids If the patient has returned to work If the patient has improved functioning and pain
12 Opioids Defined Morphine Equivalent Dosage (MED) A method developed to adjust for the various potency of opioids into a common measurement (morphine, which would be a 1:1 ratio) Per ODG, the Factor to be used when calculating MED Codeine Fentanyl (Actiq) oral transmucosal - 10 Fentanyl (Duragesic) transdermal (in mcg/hr) Hydrocodone - 1 Hydromorphone - 4 Methadone, 41 to 60mg per day - 10 Methadone, >60mg per day - 12 Morphine - 1 Oxycodone (OxyContin) Oxymorphone (Opana) 3 (Quantity / Day Supply) = Daily Pill Count * Dosage * MED Factor = MED
13 The Cocktail But Opioids aren t the only problem NSAID (non-steroidal anti-inflammatory drug) Long-term use can cause kidney failure and/or liver failure Prescriptions where OTC would suffice Examples: Flector patches, Voltaren (Diclofenac Sodium), Celebrex (Celecoxib), Ketoprofen, Mobic (Meloxicam), Relafen (Nabumetone) Skeletal Muscle Relaxants Should not be used for more than 2 contiguous months Soma/Carisoprodol metabolize into an addictive drug Examples: Soma (Carisoprodol), Amrix (Cyclobenzaprine), Valium (Diazepam), Lioresal (Baclofen), Skelaxin (Metaxalone), Zanaflex (Tizanidine) Benzodiazepines Weaning can take up to 18 months First time they are prescribed, Case Management should be involved Examples: Alprazolam (Xanax), Clonazepam (Klonopin), Diazepam (Valium), Lorazepam (Ativan), Temazepam (Restoril)
14 The Cocktail PAIN Oxycontin Fentanyl? Insomnia Lethargy Atrophy Depression Weight gain Sexual dysfunction Constipation Addiction Ambien Provigil Soma Cymbalta Bariatric surgery Viagra Doc-Q-Lase Suboxone All of this makes the pain harder to identify and treat
15 Inappropriate Treatment Patterns Treatment Red Flags Opioid dosage exceeding 120mg MED (morphine equivalent dosage) per day Acetaminophen dosage exceeding 4000mg per day NSAID dosage exceeding 3200mg per day Opioids used for more than 2 contiguous months after surgery Muscle relaxants used for more than 2 contiguous months NSAIDs used for more than 6 contiguous months Benzodiazepines used for more than 4 contiguous weeks Topical analgesics Anti-narcoleptic drugs (Provigil, Nuvigil) Hormonal supplements Spinal Cord Stimulator / Intrathecal Pump and topical / oral analgesics Drug regimen that has automatic refills More than one prescribing physician involved in the overall drug regimen No opioid treatment agreement No urine drug monitoring No liver / kidney toxicity tests where applicable
16 The Weaning Process More Art than Science Detox/weaning/FRP has become a four-letter word for Work Comp Two primary contributors to success 1. Motivation of the patient 2. Competence of the provider
17 The Weaning Process Before Health assessment General medical, psychiatric and surgical history What drugs in addition to opioids are being taken? Risk assessment before the process starts Patient motivation Psychological dependence, anxiety Level of medical oversight required In-patient / out-patient Goals Reduction in dosage or removal of drugs Identify how patient will manage pain with less/no dosage Patient education Explain Risks and potential benefits Develop realistic expectations Per the AMA Guides March/April 2011 Newsletter, 21 of 23 patients in the study reported a significant decrease in pain after detoxification
18 The Weaning Process Selection Appropriate setting Cognitive Behavioral Therapy (CBT) Functional Restoration / Chronic Pain Management program In- or out-patient detox Can the treating physician facilitate the weaning? Has success been defined? If not, consider the following when selecting a facility: Is there a multi/inter-disciplinary approach? Do they offer alternative treatments (e.g. yoga)? Do they have in-patient access for significant addiction/health issues? Are patients assessed and sometimes denied entry? Are treatment plans customized per patient? Are changes in vital signs and function and pain control objectively measured and recorded daily? If inadequate progress are adjustments made? Are patients followed for at least one year post-discharge?
19 The Weaning Process During Withdrawal Generally not life threatening but can be very unpleasant Symptoms may include Vomiting, diarrhea, abdominal cramps Anxiety and agitation Muscle twitching and Restlessness Insomnia Flu-like symptoms Increased pain Per ODG, for patients that are not addicted and on relatively low dosage Taper by 20-50% per week Otherwise a slower process is suggested 10% every 2-4 weeks, down to 5% once ⅓ the original dosage There may be greater success if the patient is first switched to ER / LA drugs Each patient is different in response and duration
20 How to Implement Change Peer-to-peer, collegial, evidence-based Leverage PBM system, customize the formulary Consistent, coordinated, teambased follow up on changes Focus on prescriber, patient & claims professional The goal should be to: Remove impediments for appropriate drugs Discontinue/reduce inappropriate drugs Increase function and quality of life for the patient
21 Mark Pew Senior Vice President, Product Development (678) Office Our Evidence Based blog
Tapering Injured Workers off Prescription Drugs
www.prium.com Tapering Injured Workers off Prescription Drugs Learning Objectives 1. Define polypharmacy complexities 2. Explain the biopsychosocial model 3. Outline the weaning process 4. Examine real
More information20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days
Pre - PA Allowance Quantity Extended Release Tablets or Capsules 90 MME/day Medication Strength Avinza (morphine) 60mg, 75mg, 90mg Embeda (morphine /naltrexone) 50/2mg, 60/2.4mg, 80/3.2mg Exalgo (hydromorphone)
More informationManaging Narcotics on Workers Comp Claims. Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc.
Managing Narcotics on Workers Comp Claims Presented By: Craig S. Stern, PharmD, MBA President Pro Pharma Pharmaceutical Consultants, Inc. October 21, 2014 Outline Rationale Scope list drug list Recommended
More informationUp and Away with Opioids
Up and Away with Opioids id A clinical discussion about use and abuse Presented by: Michael Giusani, R.Ph. Clinical Pharmacist RJ Health Systems (a partner of ScripNet) Michael Seise, PharmD Clinical Pharmacist
More informationShining a Light on MEDs Understanding morphine equivalent dose
Shining a Light on MEDs Understanding morphine equivalent dose In the workers compensation industry, 60.2 percent of claimants utilize opioid analgesics for the treatment of pain caused by a workplace
More information``Considerations for using opioid drug therapy in workers compensation include patient safety, drug effectiveness and financial impacts
Opioids Effective Case Management Opioids RELEVANCE IN WORKERS COMP Opioids are a diverse group of drugs that represent the strongest pain medications available. They are frequently prescribed for pain
More informationBlueprint for Prescriber Continuing Education Program
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
More informationsolutions MEDICATION MIS MANAGEMENT and Chronic Pain 10/4/2016 Opioid Abuse: Current Data Opioid Abuse: Current Data
MEDICATION MIS MANAGEMENT and Chronic Pain solutions Opioid Abuse: Current Data Americans consume 80% of the global supply of opioids This includes 99% of the world s hydrocodone and 2/3s of the world
More informationOpioid Analgesics. Recommended starting dose for opioid-naïve patients
Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote
More informationSoma (carisoprodol), Soma Compound (carisoprodol and aspirin), Soma Compound w/ Codeine (carisoprodol and aspirin and codeine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.07 Subject: Soma Page: 1 of 7 Last Review Date: September 15, 2017 Soma Description Soma (carisoprodol),
More informationPrescription Drug Abuse: Colorado and Nationwide
Prescription Drug Abuse: Colorado and Nationwide Eric Lavonas, MD Associate Director, Rocky Mountain Poison and Drug Center Associate Professor, University of Colorado School of Medicine 1 What s the Problem?
More informationPrior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
More informationPrior Authorization for Opioid Products Indicated for Pain Management
Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax
More informationPrescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM. Preventative Education: Substance Use Disorder
Prescription Drugs MODULE 5 ALLIED TRADES ASSISTANCE PROGRAM Preventative Education: Substance Use Disorder Misuse of prescription pain relievers is, after marijuana use, the second most common form of
More informationPractical Pain Management Leah Centanni, MSN, FNP-C, Asst. Clinical Professor CANP Conference March 22, 2014
Practical Pain Management Leah Centanni, MSN, FNP-C, Asst. Clinical Professor CANP Conference March 22, 2014 Overview Types of Pain Physical Examination of Pain Pharmacologic Approach in Pain Management
More information2016 Drug Trends Series
Drug Trends Series Part 3: Assessing opioids and compounds Published August 2017 1 Drug Trends Series Opioids & Compounds First Script Introduction As with the first two editions in Coventry s Drug Trends
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationMorphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone
More information2009 Workers' Compensation Drug Trend Report. An analysis of trend and a forecast for the future
2009 Workers' Compensation Drug Trend Report An analysis of trend and a forecast for the future Published April 2010 LEAD AUTHORS Emily Cox, PhD, RPh Yakov Svirnovskiy Jennifer Kaburick, RN Ruth Martinez,
More informationSoma (carisoprodol), Soma Compound (carisoprodol and aspirin), Soma Compound w/ Codeine (carisoprodol and aspirin and codeine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.07 Subject: Page: 1 of 7 Last Review Date: September 15, 2016 Description (carisoprodol), Compound
More informationSession II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids
Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be
More informationRule Governing the Prescribing of Opioids for Pain
Rule Governing the Prescribing of Opioids for Pain 1.0 Authority This rule is adopted pursuant to Sections 14(e) and 11(e) of Act 75 (2013) and Sections 2(e) and 2a of Act 173 (2016). 2.0 Purpose This
More information9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A
Prescription Drug Abuse Crises Outline 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A 1 1970s 1980s 2 The 1990s OXYCODONE Oxycodone/APAP OxyContin
More informationRisk Reduction Strategies in Pain Management
Risk Reduction Strategies in Pain Management Melissa J. Durham, PharmD, MACM, BCACP, DAAPM Assistant Professor of Clinical Pharmacy USC School of Pharmacy Clinical Pharmacist, The USC Pain Center Learning
More information2018 Annual Meeting & Educational Conference Opioids In Workers Compensation: Research From WCRI
2018 Annual Meeting & Educational Conference Opioids In Workers Compensation: Research From WCRI John W. Ruser, Ph.D. NCSI 2018 Annual Meeting June 12, 2018 AGENDA Introduce WCRI Opioid dispensing to injured
More informationSubject: Pain Management (Page 1 of 7)
Subject: Pain Management (Page 1 of 7) Objectives: Managing pain and restoring function are basic goals in helping a patient with chronic non-cancer pain. Federal and state guidelines require that all
More information10 BEFORE THE MEDICAL BOARD OF CALIFORNIA Kimberly Kirchmeyer ("Complainant") brings this Accusation solely in her official
2 3 4 5 6 7 XAVIER BECERRA Attorney General of California MATTHEW M. DAVIS Supervising Deputy Attorney General JOHNS. GATSCHET Deputy Attorney General State Bar No. 244388 California Department of Justice
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationPAIN. TREATMENT TABLES Analgesics. NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose
NON-OPIOID SHORT-ACTING LONG-ACTING **** O PAIN TREATMENT TABLES Analgesics NON-OPIOID ANALGESICS Generic Name Trade Names (Examples) Duration Initial Dose Tramadol 50 mg Ultram Every 4 hours 1-2 tabs,
More informationKnock Out Opioid Abuse in New Jersey:
Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids
More informationPharmacy Medical Necessity Guidelines: Opioid Analgesics
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationClinical Policy: Opioid Analgesics Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid
Clinical Policy: Reference Number: OH.PHAR.PPA.13 Effective Date: 10/2017 Last Review Date: 6/2018 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCurbing Prescription Drug Abuse in Medicaid
Curbing Prescription Drug Abuse in Medicaid Joint Legislative Health Care Oversight Committee October 12, 2010 Dr. Lisa Weeks, BSPharm, PharmD Pharmacy and Ancillary Services Division of Medical Assistance
More informationFocus on Pharmacy Management
NEW INSIGHTS FOR PAIN MANAGEMENT 1 I. Introduction CorVel s series illuminates the many facets of challenges faced in our industry. Each article shares best practices, tools and approaches payors may use
More informationH NDS-ONHealth. Prescription Drug Abuse. Drug overdose death rates in the United States have more than tripled since 1990 and have never been higher.
H NDS-ONHealth Health Wave Newsletter, October 2013 Visit us on our website at www.healthwaveinc.com Drug overdose death rates in the United States have more than tripled since 1990 and have never been
More informationPharmacy Trend Analysis
Pharmacy Trend Analysis Drug Utilization took out subtitle and Spending Trends in Workers Compensation Inside Introduction... 1 No Script Unmanaged. No Injured Worker Left Behind... 2 External Influences
More informationLegacy Pain Management Center New Patient Questionnaire
Legacy Pain Management Center New Patient Questionnaire Please complete this form prior to your visit to allow us to make the best use of our time together. Primary Care Provider: Referring Physician:
More informationEXTENDED RELEASE OPIOID DRUGS
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),
More informationNBPDP Drug Utilization Review Process Update
Bulletin # 802 December 1, 2010 NBPDP Drug Utilization Review Process Update The New Brunswick Prescription Drug Program (NBPDP) employs a Drug Utilization Review (DUR) process which identifies, investigates
More informationDrug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans
FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA
More informationTechnician Training Tutorial: Safety Considerations with Opioids
(Page 1 of 5) Technician Training Tutorial: Safety Considerations with Opioids Opioids as a drug class are considered to be high-alert drugs. This class includes codeine, methadone, oxycodone, etc. When
More informationPrescription Drug Misuse/Abuse in Seniors. April Rovero Founder/Executive Director
Prescription Drug Misuse/Abuse in Seniors April Rovero Founder/Executive Director Deaths per 100,000 Population 30 25 Overdose Demographics Drug Poisoning Death Rates by Age: United States (2010) 20 15
More informationUSUAL DOSE OF XANAX. Usual Dose Of Xanax
USUAL DOSE OF XANAX Usual Dose Of Xanax Withdrawal what symptoms xanax from Compared valium to xanax.5 Valium vs vs xanax ativan Gocce mg 0 xanax 25 quante Melatonin between and xanax interactions Lb xanax
More informationReducing Opioid Over- Prescribing in a Large Integrated Health Care System
Session L6 This presenter has nothing to disclose It Takes a Village to Curb the Prescription Opioid Epidemic: Reducing Opioid Over- Prescribing in a Large Integrated Health Care System Joel D. Hyatt,
More informationCLINICAL POLICY Clinical Policy: Extended Release Opioid Analgesics
Reference Number: AZ.CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid- AHCCCS Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationA nation in pain: Focus on Medicaid
DATA INSIGHTS A nation in pain: Focus on Medicaid Opioid pain medications have become one of the most controversial classes of prescription therapy. While they provide great benefits in controlling both
More informationusing analytics to identify and strategically manage patient opioid abuse
using analytics to identify and strategically manage patient opioid abuse Philip Finocchiaro, MD, FACP Senior Medical Director, Quality and Clinical Outcomes Verscend Olivia Mapplethorpe Senior Client
More information: Opioid Quantity Limits
March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected
More informationNo Pain, No Gain Pharmacy Patient Pain Counseling Competition
No Pain, No Gain Pharmacy Patient Pain Counseling Competition Offered by the Maine Pharmacy Association as part of the 2010 MPA Fall Conference Sponsored by an educational grant by NASPA and Purdue Pharma,
More informationOPIOID PRESCRIBING RULES
OPIOID PRESCRIBING RULES FOR WORKERS COMPENSATION - MAY 2018 THE RULES: IN EFFECT MAY 1, 2018 APPLY TO: [CSRS REQUIREMENT: IN EFFECT NOVEMBER 1, 2018] Opioid prescriptions and outpatient pain management
More informationBree Collaborative AMDG Opioid Prescribing Guidelines Workgroup. Opioid Prescribing Metrics - DRAFT
Bree Collaborative AMDG Opioid Prescribing Guidelines Workgroup Opioid Prescribing Metrics - DRAFT Definitions: Days Supply: The total of all opioid prescriptions dispensed during the calendar quarter
More informationAPPENDIX E: HEALTHCARE PRACTITIONER- REPORTED REDUCTION OF PAIN MEDICATION
Contents Appendix E: Healthcare Practitioner-Reported Reduction of Pain Medication... E-1 Appendix E: Healthcare Practitioner- Reported Reduction of Pain Medication Note: Word choice and spellings have
More informationOpioid Pain Contracts: A Resident Driven Quality Improvement Project
Opioid Pain Contracts: A Resident Driven Quality Improvement Project A Response to the Opioid Epidemic Dr. Phillip Knouse Dr. Victoria Montgomery Disclosure None Objectives Discuss the current Opioid Epidemic
More informationDrug Use Evaluation: Short Acting Opioids (SAO)
Drug Use Evaluation: Short Acting Opioids (SAO) Summary Short acting opioid analgesics are one of the most prescribed (top 10) and highest cost (top 20) medication classes for the Oregon Fee For Service
More informationOpioid Management of Chronic (Non- Cancer) Pain
Optima Health Opioid Management of Chronic (Non- Cancer) Pain Guideline History Original Approve Date 5/08 Review/Revise Dates 11/09, 9/11, 9/13, 09/15, 9/17 Next Review Date 9/19 These Guidelines are
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More information1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I
chedule II Controlled ubstances: Basics and Beyond James L. Besier, Ph.D., R.Ph., FAHP Adjunct Associate Professor College of Nursing Adjunct Assistant Professor James L. Winkle College of Pharmacy University
More informationOpioid Management Program May 2018
Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily
More informationRP PERCOCET STREET VALUE
RP 5 325 PERCOCET STREET VALUE Rp 5 325 Percocet Street Value Max dose of percocet a day Urgent care percocet bothell wa 98012 directions I need a substitute for percocet 10/325 percocet Percocet constipation
More informationSpotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017
Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic October 25, 2017 Disclosures and Disclaimer Neither the Institute for Health Policy and Leadership (IHPL) nor I have any relevant financial
More informationREB CLOSE, MD Community Hospital of the Monterey Peninsula
REB CLOSE, MD Community Hospital of the Monterey Peninsula The Scope of the Problem 1-5 Opiate use in the US 80% of the world s prescription opiate supply 99% of the world s hydrocodone supply From 1997
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl
More informationOpioid Management Program October 2018
Opioid Management Program October 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of
More informationA Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse
A Statewide Evaluation of Opioid Prescribing Patterns with an Emphasis on Drug Diversion and Substance Abuse INVESTIGATIVE TEAM: STEERING COMMITTEE FOR THE TUFTS HEALTH CARE INSTITUTE ON OPIOID RISK MANAGEMENT
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCONFRONTING THE OPIOID EPIDEMIC. e-book: Introducing OptumRx Opioid Risk Management
CONFRONTING THE OPIOID EPIDEMIC 2 0 1 8 OPIOID ABUSE IS A CRISIS IN THE U.S. OptumRx Opioid Risk Management attacks this complex, deeply embedded problem with a comprehensive approach featuring five interrelated
More informationBest Practices in Prescribing Opioids for Chronic Non-cancer Pain
Best Practices in Prescribing Opioids for Chronic Non-cancer Pain Disclosures S C O T T S T E I G E R, M D, F A C P, D A B A M A S S I S T A N T C L I N I C A L P R O F E S S O R D I V I S I O N O F G
More informationTapering Opioids Best Practices*
Tapering Opioids Best Practices* Chuck Hofmann, MD, MACP 5 th Annual EOCCO Office Staff and Provider Summit September 28, 2017 Disclosure No Conflicts of Interest to report Learning Objectives Understand
More informationGeneric Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE
STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise
More informationOxymorphone (Opana ) is indicated for the relief of moderate-to-severe acute pain where the use of an opioid is appropriate.
Page 1 of 7 Policies Repository Policy Title Policy Number Schedule II Prior Authorization FS.CLIN.16 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on
More informationOpioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory
Opioids: Use, Abuse and Cause of Death Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory jharmon@occl.ocgov.com Opioid: Any psychoactive chemical that resembles morphine
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Opioid Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective Date..1/1/2018 Next
More informationMedication trends shaping workers compensation. A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 mid-year review of the prevailing industry influences impacting pharmacy outcomes OPTUM WORKERS COMPENSATION DATA SET Analysis of our data, the industry
More informationTop 10 narcotic pain pills
Top 10 narcotic pain pills Click to go to the item or just scroll down the page. Doctors Respond to FDA Panel Recommendations FDA Considers Banning Popular Prescription Pain Medications and. Top 10 Natural
More informationConversion chart from fentanyl to opana er
Conversion chart from fentanyl to opana er (e.g., Nucynta). Both opioid products involved in conversion are one of the following: morphine, oxycodone, oxymorphone, hydromorphone (not extended- release),
More informationPrescription Opioid Addiction
CSAM-SCAM Fundamentals Prescription Opioid Addiction Presentation provided by Meldon Kahan, MD Family & Community Medicine University of Toronto Conflict of interest statement I received funds from Rickett
More informationOpioids: Use and Misuse/Steven Feinberg, MD; Scott Levy, MD, MPH, FACOEM
Western Occupational Health Conference September 14, 2012 Opioid - Use & Misuse Scott Levy, MD MPH FACOEM Steven Feinberg, MD, MPH Disclosure Information Western Occupational Health Conference 2012 Steven
More informationResponding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team
Responding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team Cheryl L Mejta, Ph.D. Nancy H Burley, Ed.D. Serena Wadhwa, Psy. D., LCPC, RYT, CADC Objectives Identify
More informationResponding to The Joint Commission Alert on Safe Use of Opioids in Hospitals
Responding to The Joint Commission Alert on Safe Use of Opioids in Hospitals Suzanne A Nesbit, PharmD, CPE Clinical Pharmacy Specialist, Pain Management The Johns Hopkins Hospital Objectives and Disclosures
More informationInitial Pain Questionnaire
Initial Pain Questionnaire Date: Name: Address: Last First Middle Initial Street Address City State Zip Home Phone Cell : Work: Referring Physician: Other Physicians: Age: PAIN HISTORY: What is the main
More informationNew Guidelines for Prescribing Opioids
New Guidelines for Prescribing Opioids Keeping Your Claimants Safe Presented by: Dr. Mitch Freeman, Pharm.D. Chief Clinical Officer, Pharmacy Solutions Agenda The Opioid Challenge Today How We Got Here
More informationTechnician Tutorial: Scheduled Drugs
(Page 1 of 8) Technician Tutorial: Scheduled Drugs In the U.S., the federal Controlled Substances Act (CSA) regulates controlled substances. The U.S. Drug Enforcement Administration (DEA), which is a part
More informationA National Perspective on the Abuse and Diversion of Prescription Drugs
A National Perspective on the Abuse and Diversion of Prescription Drugs Hilary L. Surratt, Ph.D Steven P. Kurtz, Ph.D. ARSH: Center for Applied Research on Substance Use and Health Disparities Faculty
More informationAddressing the Opioid Epidemic: Prescribing Opioids for Non-Cancer Pain
Addressing the Opioid Epidemic: Prescribing Opioids for Non-Cancer Pain Ajay D. Wasan, MD, MSc Professor of Anesthesiology and Psychiatry Vice Chair for Pain Medicine, Department of Anesthesiology University
More informationLong-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018
Long-Acting Opioid Policy Number: 5.02.519 Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for long-acting
More informationIS PERCOCET GOOD TATTOO PAIN RELIEVER FOR DOGS
IS PERCOCET GOOD TATTOO PAIN RELIEVER FOR DOGS Is Percocet Good Tattoo Pain Reliever For Dogs Can u mix percocet and suboxone Take suboxone with percocet How much does percocet prescription cost Oxycodone
More informationDrug Overdoses A Public Health Problem. Marianne Cloeren, MD, MPH, FACOEM, FACP 10/2/2013. Objectives
Drug Overdoses A Public Health Problem Marianne Cloeren, MD, MPH, FACOEM, FACP 10/2/2013 Objectives O Provide an overview of the trends in opioid prescriptions and impact O Consider implications for the
More informationCODEINE COUGH SYRUP AND XANAX
CODEINE COUGH SYRUP AND XANAX Codeine Cough Syrup And Xanax Xanax worse coke what's or Reviews xanax anxiety on for Xanax is needed when Bars blue xanax are real 1mg xr xanax dosage Bad not to it prescribed
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 4000-3 Program Opioid Overutilization Cumulative Drug Utilization Review Criteria Medication Includes all salt forms, single and
More informationCONCERNED ABOUT TAKING OPIOIDS AFTER SURGERY?
CONCERNED ABOUT TAKING OPIOIDS AFTER SURGERY? ASK YOUR DOCTOR ABOUT EXPAREL FOR LONG-LASTING, NON-OPIOID PAIN RELIEF. VISIT EXPAREL.com/patient FOR MORE INFORMATION. YOU HAVE A SAY IN HOW YOUR PAIN IS
More informationPROVIDER BULLETIN. Published by Wyoming Workers Compensation Medical Case Management Unit October 21, 2015
Matthew H. Mead Governor State of Wyoming Department of Workforce Services DIVISION OF WORKERS COMPENSATION 1510 East Pershing Boulevard, South Wing Cheyenne, Wyoming 82002 http://www.wyomingworkforce.org
More informationMedicare Part D Opioid Policies for 2019 Information for Patients
CENTERS FOR MEDICARE & MEDICAID SERVICES Medicare Part D Opioid Policies for 2019 Information for Patients Introduction Prescription opioid pain medications like oxycodone (OxyContin ), hydrocodone (Vicodin
More informationDr. Smith. Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force
Dr. Smith Roneet Lev, MD FACEP Chief, Emergency Department Scripps Mercy Hospital Chair, San Diego Prescription Drug Abuse Medical Task Force 1 1 How We Got Here 2 The Epidemic 3 4 San Diego Death Diaries
More informationten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment
ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment This booklet was created to help you learn about tapering. You probably have lots
More informationPrescription Drug Dispensing in Oregon
Drug Dispensing in Oregon January 1, 2012 - December 31, 2012 Schedules II-IV Medications Dispensed in Oregon Linn County PUBLIC HEALTH DIVISION Drug Monitoring Program Drug Dispensing in Oregon: January
More informationMEDICAL ASSISTANCE BULLETIN
ISSUE DATE September 4, 2015 SUBJECT EFFECTIVE DATE September 9, 2015 MEDICAL ASSISTANCE BULLETIN NUMBER *See below BY Prior Authorization of Analgesics, Narcotic Long Acting and Analgesics, Narcotic Short
More informationSlide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
More informationSCG1 Evaluation of High Risk Pain Medications for MME
2018 SCG Health QCDR Measure Specifications 1 SCG1 Evaluation of High Risk Pain Medications for MME Percentage of patients aged 18 years and older prescribed and actively taking one or more high risk pain
More information